PHIA Koninklijke Philips N.V.
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.…
Industry Peers
Medical DevicesKey Statistics
About Koninklijke Philips (AMS: PHIA)
›
Koninklijke Philips (AMS: PHIA) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 63,909 employees.
The shares were at 26.77 EUR on 19 November 2026, up 14.3% over 52 weeks. Its 52-week range is 20.90 EUR to 28.03 EUR: the price is 4.5% below the high and 28.1% above the low.
At a market capitalisation of 26.17B EUR, it trades at 27.0 times trailing earnings and 15.4 times forward earnings. The median trailing P/E of its 18 largest Medical Devices peers is 25.2, so PHIA is valued in line with them. It pays a dividend yielding 3.13% (it pays out 86% of its earnings), against a median of 1.97% among the dividend payers in that peer group.
Koninklijke Philips reports return on equity of 8.2%, an operating margin of 8.8% and revenue up 2.1% year over year.
Its debt exceeds its cash by 5.39B EUR, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 28.05 EUR is 4.8% above the current price. The next earnings report is expected on 9 February 2027.